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Copyright © 200? JCBN Summary A palatinose-based liquid formula (palatinose-formula), suppresses postprandial
plasma glucose and insulin levels in healthy men. The objective of this study was to investigate
the effects of long-term palatinose-formula ingestion on glucose metabolism in patients
with impaired glucose tolerance (IGT) or type 2 diabetes. Two patients with IGT and 7 patients
with type 2 diabetes participated in the palatinose-formula and dextrin-based liquid formula
(dextrin-formula) loading test and long-term palatinose-formula administration study. After a
3-month control period, palatinose-formula (1046 kJ) was ingested daily by patients as a part
of breakfast for 5 months. In the loading test, palatinose-formula suppressed postprandial
plasma glucose and insulin levels and areas under the curve compared with those after
dextrin-formula ingestion. In the long-term study, glycated hemoglobin levels (after 3 months
and 5 months of treatment) and serum 8-hydroxydeoxyguanosine levels (after 5 months of
treatment) were markedly decreased comparing with those at baseline. Intake of 1046 kJ
palatinose-formula as a part of breakfast over a long-term period may be effective for
improvement of glucose metabolism in patients with IGT or type 2 diabetes.
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Introduction
Type 2 diabetes mellitus is a major health problem associ-
ated with excess morbidity and mortality, resulting in sub-
stantial health-care costs [1]. Treatment of type 2 diabetes
has traditionally focused on control of fasting plasma glucose;
in recent years, the management of postprandial hyper-
glycemia has been thought to be a more important target.
Glycated hemoglobin (HbA1c) levels are closely associated
with postprandial glucose levels in type 2 diabetes, in com-
parison with fasting glucose levels [2]. Anti-hyperglycemicM. Sakuma et al.
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therapy focused on control of postprandial glucose level
has a greater impact on overall metabolic control, and thus
improves long-term outcome compared with the more tradi-
tional approaches focused on fasting glucose level [3]. Post-
prandial hyperglycemia has been associated with increased
risk of microvascular [4–6] and macrovascular [7–10]
complications. In recent years, cohort studies have shown
that postprandial hyperglycemia is an independent risk
factor for cardiovascular disease [11–13]. In the STOP-
NIDDM study, correction of postprandial hyperglycemia
reduced the onset of myocardial infarction [14].
The glycemic index (GI), originally described by Jenkins
et al. [ 15], is a ranking of carbohydrates based on their
immediate effects on blood glucose levels. Epidemiologic
studies demonstrated that the dietary GI would be an impor-
tant factor in preventing non-insulin-dependent diabetes
[16, 17]. The beneficial effects of a low-GI diet have been
demonstrated over both the short- and long-term for normal
subjects and patients with diabetes [18–21]. It is difficult for
individuals to strictly control every meal. Therefore, if a
special meal is only given once a day, it could be useful to
lower the postprandial serum glucose level and improve
compliance. The quality of breakfast is thought to be the
most important for improvement of glycemic control, because
patients with diabetes require more insulin for breakfast
than for an isocaloric midday or evening meal [22,  23].
Moreover, it has been reported that insulin sensitivity in
individuals with diabetes fluctuated, with decreases from
the night to morning and increases during the day [24].
A palatinose-based liquid formula (palatinose-formula,
Inslow®: Meiji Dairy Products; Tokyo, Japan) is a recently
developed liquid dietary product that contains palatinose.
Palatinose a sucrose isomer found in honey [25], are
metabolized by isomaltase, and less rapidly, but completely,
cleaved in the intestine than sucrose [26]. Ingestion of
palatinose by type 2 diabetic humans and rats resulted in a
reduction in their postprandial plasma glucose and insulin
levels [27,  28]. Consumption of palatinose-formula at
breakfast appears to improve glycemic control by reducing
postprandial plasma glucose and insulin levels after lunch
(second meal effect) in healthy men [29]. However, it is not
clear that the effect of continuous palatinose-formula intake
at breakfast improves glucose metabolism in patients with
impaired glucose tolerance (IGT) or type 2 diabetes. In this
study we investigated the effects of long-term palatinose-
formula ingestion as a part of breakfast on glycemic control
and body composition in patients with IGT or type 2 diabetes.
Experimental Procedures
Liquid formulas
Palatinose-formula was prepared by partially replacing
dextrin in the dextrin-based liquid formula (dextrin-formula)
with 55.7% palatinose. The detailed composition is shown in
Table 1; it included palatinose, dextrin, xylitol, dietary fiber,
and mixed carbohydrates. The protein, fat, and carbohydrate
% of energy were 20.0%, 29.7%, and 50.3%, respectively.
The control formula was a dextrin-formula that also contained
sucrose; the protein, fat, and carbohydrate % of energy were
14.0%, 31.0%, and 55.0%, respectively (Table 1).
Subjects and study design
The study was performed after obtaining written informed
consent from all patients, and was approved by the Ethics
Committee of the University of Tokushima. The protocol
conformed to the Helsinki Declaration. Two patients with
impaired glucose tolerance (IGT) (2 females) and 7 patients
with type 2 diabetes (3 males and 4 females) participated in
Table 1. Energy composition of the test formulas
Palatinose-formula Dextrin-formula
Energy (kJ/ml) 4.18 4.18
Protein (% of energy) 20.0 14.0
Fat (% of energy) 29.7 31.0
Carbohydrate (% of energy) 50.3 55.0
Main carbohydrate composition Palatinose (55.7%) Dextrin (97.2%)
Table 2. Subject Characteristics
Values are means ± SE, n =9 .
Characteristics Values
Impaired glucose tolerance (male/female) 0/2
Type 2 diabetes mellitus (male/female) 3/4
Age (years) 63.4 ± 3.0
Body weight (kg) 63.8 ± 2.5
Body mass index (kg/m2) 25.0 ± 0.8
Body fat ratio (%) 28.2 ± 2.2
Fasting plasma glucose (mmol/L) 7.76 ± 0.45
Fasting insulin (pmol/L) 32.4 ± 3.0
HbA1c (%) 6.60 ± 0.24
Triacylglycerol (mmol/L) 2.37 ± 0.40
Total cholesterol (mmol/L) 5.46 ± 0.29
HDL cholesterol (mmol/L) 1.36 ± 0.13Effect of Palatinose-based Liquid Formula
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this study. Their clinical characteristics at study entry are
shown in Table 2. Patients with abnormal renal, hepatic, or
thyroid function were excluded. Five patients were medicated
with sulfonylurea or phenylalanine derivative and 4 patients
were only received nutritional consultation. All patients
maintained any current therapies throughout the study period,
with no dosing changes. Prior to the beginning of the long-
term palatinose-formula administration study, each patient
underwent a palatinose-formula and dextrin-formula loading
test.
Loading test
The loading test had a crossover design, with a one-week
washout period between dosing episodes. Each patient
consumed both palatinose-formula (250 ml; 1046 kJ) and
dextrin-formula (250 ml; 1046 kJ). The patients came to the
University of Tokushima at 0830 h after a 12-h overnight
fast. Patients completely consumed the liquid formula
within a 5-min period. Peripheral venous blood samples
were collected at times 0 (before ingestion), and 30, 60, 90,
120, and 180 min after ingestion of the formula. Blood
samples were used for analysis of plasma glucose and
insulin concentration.
Long-term study
The long-term study was carried out after a 3-month
control period (from Month -3 to Month 0). The first month
of the control period (from Month -3 to Month -2) was
established to determine individual patient energy intake.
Each patient’s energy intake and dietary habits were deter-
mined from daily dietary records. Patients received individual
counseling on dietary food intake and were recommended
to reach a goal of a stable and reasonable energy intake. A
2-month control period (from Month -2 to Month 0) was
arranged after the patients’ quantity of energy intake was
stabilized. After the control period, patients ingested
palatinose-formula for 5 months (test period). During the
test period, patients were instructed to maintain the quantity
of total energy intake and substituted a palatinose-formula
dose for 1046 kJ of their breakfast. The total energy of the
breakfast in the test period was fixed to the control period
(from Month -2 to Month 0) quantity based on each patient’s
dietary record. Patients were asked to maintain a constant
lifestyle and keep a dietary record to be completed during
the 3 days prior to each scheduled visit to the University of
Tokushima. Visits were scheduled at Month -3, Month -2
(control period), and at Month 0 (baseline), 3, and 5 for
collection of fasting blood samples, body composition
measurement, and to hand in their previous 3-day’s dietary
records. Blood samples were used for analysis of fasting
plasma glucose, fasting insulin, HbA1c, total cholesterol,
HDL cholesterol, triacylglycerol, adiponectin and 8-
hydroxydeoxyguanosine (8-OHdG) concentrations. A dieti-
cian calculated the quantity of intake energy from each
patient’s dietary records and determined the mean value for
the 3 days leading up to the scheduled clinic visit.
Analytic methods
Body composition with respect to lean and fat mass was
determined using a bioelectrical impedance analysis method
(In Body 3.0; MP JAPAN, Tokyo, Japan).
Plasma samples were kept at −20°C until analyzed.
Plasma glucose concentration was measured by using a
glucose oxidase-based autoanalyzer. Serum insulin concen-
tration was measured by a standard radioimmunoassay. The
total incremental area under the curve (AUC) for plasma
glucose and insulin were calculated for a 180-min period
after ingestion of each liquid formula. The insulin resistance
index was calculated using the homeostasis model assess-
ment for insulin resistance (HOMA-IR = fasting insulin
(μU/ml) × fasting glucose (mmol/L) / 22.5).
HbA1c concentration was determined by high-performance
liquid chromatography; serum triglyceride, total cholesterol,
and HDL cholesterol concentrations were determined by
enzymatic techniques using a Hitachi Model 736 auto-
analyzer (Mito, Japan). Serum adiponectin concentrations
were measured by human adiponectin ELISA kit (Otsuka
Pharmaceutical Co, Ltd, Tokyo, Japan). Serum 8-OHdG
concentrations were measured by high sensitive 8-OHdG
ELISA kit (Japan Institute for the Control of Aging, Nikken
SEIL Co., Ltd. Fukuroi; Shizuoka, Japan).
Statistical analyses
Data are presented as mean ± standard error of the mean
(SE). The loading test was analyzed using Student’s t test for
paired comparisons. The long-term study was analyzed using
Wilcoxon matched-pairs signed-rank test. All statistical
analyses were performed with Stat View for Windows,
version 5.0 (SAS Institute; Cary, NC).
Results
Loading test
The effects of palatinose-formula administration on
postprandial glucose and insulin levels were confirmed in
patients with IGT and type 2 diabetes. Postprandial plasma
glucose concentrations after palatinose-formula loading
were significantly lower than those after dextrin-formula
loading at 30 min (p<0.01), 60 min (p<0.01), and 90 min
(p<0.01) post-dosing (Fig. 1A). Postprandial insulin after
palatinose-formula loading were lower than those after
dextrin-formula loading at 30 min, 60 min, and 90 min
post-dosing, but were not significantly different (Fig. 1B).
Plasma glucose and insulin incremental AUCs after
palatinose-formula loading were significantly lower than
those after dextrin-formula loading (p<0.05; Fig. 1C, D).M. Sakuma et al.
J. Clin. Biochem. Nutr.
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Long-term study
During the long-term study, two subjects withdrew due to
conflicts of schedule and health problems unrelated to the
study, and one subject was excluded from analysis due to
poor compliance. Therefore, all long-term study data were
analyzed and are presented for the six subjects (IGT; 2
females, type 2 diabetes; 1 male and 3 females) who com-
pleted the study. Serious side effects such as anemia, renal,
or hepatic disorders did not appear during this study.
Daily intake of total energy at Month -2 decreased from
that determined at the Month -3 visit, but there was no
change in the daily total energy intake over subsequent
control and test period. Macronutrients and dietary fiber
intake from the control period to the test period did not
change (Table 3).
Anthropometric and laboratory parameters from the
beginning of control period (Month -3) to the end of the
test period (Month 5) are shown in Table 4. Body weight,
body mass index, and serum triacylglycerol concentration
significantly decreased during the control period (possibly
due to the nutritional consultation and subsequent dietary
changes). No significant changes were observed in any other
parameter during the control period. In the experimental
period, no significant changes were observed in body
weight, body mass index, body fat ratio, fasting plasma
glucose, fasting insulin, triacylglycerol, total cholesterol, or
HDL cholesterol levels. However, with intake of 1046 kJ
palatinose-formula as a part of breakfast, HbA1c and 8-
OHdG levels were significantly decreased at the Month 3
and Month 5 evaluations. HOMA-IR slightly decreased
Fig. 1. Change in plasma glucose (A) and insulin (B) concentrations after patients consumed palatinose-formula (open circle) or
dextrin-formula (closed circle). Incremental AUC for plasma glucose (C) and insulin (D) levels are shown for subjects after
they consumed palatinose-formula or dextrin-formula. Values are means ± SE, n = 9. * Difference between palatinose-formula
and dextrin-formula at that time point, p<0.05. ** Difference between palatinose-formula and dextrin-formula at that time
point, p<0.01.Effect of Palatinose-based Liquid Formula
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and adiponectin slightly increased by palatinose-formula
ingestion, although these changes were not statistically
significant.
Discussion
In this study, postprandial glucose and insulin levels after
the ingestion of palatinose-formula diet were significantly
lower than those after the ingestion of dextrin-formula diet
in patients with IGT or type 2 diabetes, as previously
observed in rats and healthy human subjects [29, 30]. Since
energy amounts during the control and experimental periods
were unchanged, it is conceivable that the decrease in HbA1c
and 8-OHdG concentrations is due to the effect of the long-
term (5-month) ingestion of palatinose-formula as a part of
breakfast in these patients with IGT or type 2 diabetes.
There are evidences of the beneficial effects to glycemic
control of a low-GI diet in type 2 diabetes [18, 19, 21, 31],
but there are few reports of the glycemic effects of a low-GI
breakfast alone. Golay et al. found that switching from a
standard cereal (cornflakes) to slow-release starch cereal
(muesli) at breakfast for only 2 weeks improved carbo-
hydrate metabolism and reduced insulin requirements in the
insulin-treated type 2 diabetic patients [32]. In addition, it
has been suggested that the low-glycemic-index foods
consumed during the first meal improved glucose tolerance
after the second meal, so-called “second meal effect” [33,
34]. In this study, long-term ingestion of palatinose-fomula
diet as a part of breakfast decreased HbA1c concentration.
In addition, decreased in HOMA-IR and increased in serum
adiponectin level suggested that insulin sensitivity may
also be ameliorated by long-term ingestion of palatinose
formula. We previously reported that long-term ingestion of
palatinose-formula over the long-term reduced visceral fat
accumulation, improved insulin sensitivity in comparison
with dextrin-formula [30], and increased adipocyte adiponec-
tine gene expression in rats [35]. Adiponectine plays a role
in glucose metabolism and plasma adiponectin level is
Table 3. Record of dietary intake during control and test periods
Values are means ± SE, n =6 .
Control period Test period
Month -3 Month -2 Month 0 Month 3 Month 5
Energy (kJ/ml) 8335 ± 786 7690 ± 636 7577 ± 569 7627 ± 473 7707 ± 607
Protein (g/day) 76.7 ± 8.6 77.8 ± 4.9 74.5 ± 7.2 78.2 ± 3.4 71.6 ± 3.3
(% of energy) 15.4 ± 1.3 17.1 ± 0.8 16.4 ± 0.5 17.3 ± 0.6 15.8 ± 1.0
Fat (g/day) 54.1 ± 4.6 52.3 ± 5.2 47.7 ± 4.2 48.5 ± 3.5 43.1 ± 2.6
(% of energy) 24.3 ± 0.9 25.4 ± 1.5 23.3 ± 0.9 24.1 ± 2.0 21.3 ± 1.3
Carbohydrate (g/day) 291.0 ± 34.4 260.4 ± 24.4 269.5 ± 21.3 262.6 ± 24.1 287.3 ± 32.6
(% of energy) 60.3 ± 1.3 57.5 ± 1.4 60.2 ± 1.0 58.5 ± 2.3 62.9 ± 2.1
Dietary fiber (g/day) 18.9 ± 1.0 20.6 ± 1.5 21.5 ± 1.7 21.0 ± 2.3 17.5 ± 1.7
Table 4. Anthropometric and laboratory parameters during control and test periods
Values are means ± SE, n = 6. * Different from Month 0 (baseline), p<0.05.
Control period Test period
Month -3 Month -2 Month 0 Month 3 Month 5
Body weight (kg) 64.9 ± 3.4* 64.0 ± 3.2* 63.3 ± 3.4 62.2 ± 3.4 62.4 ± 3.6
Body mass index (kg/m2) 26.8 ± 1.5* 26.4 ± 1.5 26.1 ± 1.6 25.7 ± 1.6 25.8 ± 1.7
Body fat ratio (%) 33.1 ± 2.4 32.4 ± 2.4 32.0 ± 2.6 31.1 ± 2.7 31.7 ± 2.9
Fasting plasma glucose (mmol/L) 6.88 ± 0.45 6.96 ± 0.42 6.50 ± 0.26 6.73 ± 0.29 6.56 ± 0.26
Fasting insulin (pmol/L) 39.2 ± 5.1 39.4 ± 10.3 41.8 ± 7.5 32.6 ± 5.6 35.0 ± 5.4
HbA1c (%) 6.35 ± 0.18 6.20 ± 0.19 6.22 ± 0.19 5.90 ± 0.17* 5.80 ± 0.15*
HOMA-IR 1.98 ± 0.26 2.02 ± 0.51 2.00 ± 0.35 1.53 ± 0.27 1.67 ± 0.23
Triacylglycerol (mmol/L) 2.15 ± 0.45* 1.82 ± 0.32 1.51 ± 0.33 1.54 ± 0.33 1.53 ± 0.28
Total cholesterol (mmol/L) 5.35 ± 0.27 5.18 ± 0.22 5.09 ± 0.09 5.03 ± 0.13 5.19 ± 0.28
HDL cholesterol (mmol/L) 1.26 ± 0.12 1.32 ± 0.14 1.36 ± 0.17 1.28 ± 0.12 1.33 ± 0.17
Adiponectin (mg/mL) — — 4.81 ± 0.50 — 5.29 ± 0.66
8-hydroxydeoxyguanosine (nmol/L) — — 1.36 ± 0.06 — 0.93 ± 0.07*M. Sakuma et al.
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positively correlated with insulin sensitivity [36–38]. These
data suggest that long-term ingestion of palatinose-formula
diet can improve glucose tolerance, probably due to the
second meal effect.
In contrast, fasting plasma glucose levels did not change
in this study. Avignon et al. suggested that postprandial
hyperglycemia reflects better glycemic control than does
fasting plasma glucose in patients with type 2 diabetes [2].
Additionally, lowering postprandial plasma glucose
optimized overall glycemic control, thus improving long-
term outcomes when compared with simply lowering fasting
plasma glucose [3].
Serum 8-OHdG concentration after five months of treat-
ment was also significantly reduced by palatinose-formula
ingestion. Patients with type 1 and 2 diabetes have signifi-
cantly higher 8-OHdG concentrations than do control sub-
jects [39, 40]. Since 8-OHdG concentration was correlated
with HbA1c concentration [40,  41], reduced 8-OHdG
reflected improvement of glycemic control by palatinose-
formula ingestion. It is known that 8-OHdG can serve as a
sensitive biomarker of oxidative DNA damage [42]. In a
previous study, glucose fluctuations during postprandial
periods exhibited a more specific triggering effect on
oxidative stress than chronic sustained hyperglycemia in type
2 diabetes [43]. Oxidative stress triggers micro- and macro-
vascular complications [44]. Because ingesting palatinose-
formula suppressed the postprandial glucose fluctuations, it
might also reduce production of oxidative stress.
Because this study was carried out with a limited number
of subjects, further study with larger populations should be
initiated to support our findings. In conclusion, we suggest
that long-term ingestion of palatinose-formula as a part of
breakfast is effective in improving glycemic control for
patients with IGT or type 2 diabetes.
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